La Jolla Pharmaceutical Company (NASDAQ:LJPC) investors are overwhelmingly excited today after the drug maker reported compelling results from a phase 3 trial of its hypotension …
Cowen analyst Phil Nadeau is weighing in on Gilead Sciences, Inc. (NASDAQ:GILD) after the rumor mill was churning with reports that the biotech …
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) hosted an analyst meeting last night at the American Epilepsy Society (AES) meeting that was met with marked …
Nivalis Therapeutics Inc (NASDAQ:NVLS) shares are collapsing nearly 60% after the biotech firm’s cavosonstat’s Phase II proof-of-concept trial in F508del homozygous cystic fibrosis …
XOMA Corp (NASDAQ:XOMA) shares are surging forward a sturdy 5% today after delivering its third-quarter financial results. Yet, considering the biotech firm’s pipeline …
Gilead Sciences, Inc. (NASDAQ:GILD) just released top-line data from the Phase III POLARIS trials of Sofosbuvir, Velpatasvir, and Voxilaprevir in hepatitis C virus …
Yesterday morning, GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) announced the success of its second Lennox-Gastaut Syndrome Phase III trial, evaluating pipeline drug Epidiolex, the …
In a research report issued this morning, Cowen Phil Nadeau reiterated an Outperform rating on shares of Dynavax Technologies Corporation (NASDAQ:DVAX), with a price target …
XOMA Corp (NASDAQ:XOMA) just ended its second quarter, and yet, all eyes are on the biotech company’s endocrinology portfolio, specifically XOMA 358, a …
Analyst Phil Nadeau of Cowen downgraded shares of Zafgen Inc (NASDAQ:ZFGN) from Outperform to Market Perform, after the biotech company terminated one of its pipeline drugs, …
